Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats

被引:64
作者
Kask, A
Pähkla, R
Irs, A
Rägo, L
Wikberg, JES
Schiöth, HB
机构
[1] Tartu State Univ, Dept Pharmacol, EE-2400 Tartu, Estonia
[2] Uppsala Univ, BMC, Dept Pharmaceut Pharmacol, S-75124 Uppsala, Sweden
关键词
food intake; HS014; leptin resistance; MC4; antagonist; melanocortin (MC) receptor subtypes; obesity;
D O I
10.1097/00001756-199903170-00009
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
IN this study we investigated the long term effects of a potent and selective melanocortin 4 (MC4) receptor antagonist (HS014) on food intake, body weight, body composition and blood glucose levels in adult rats. HS014 was injected i.c.v. either by twice-daily injections (2 x 1 nmol) for 6 days or administered by continuous infusion with osmotic minipumps (0.16 nmol/h) for 2 weeks. The results show a considerable increase in food intake and body weight after both of the treatments without any signs of tachyphylaxis. After 2 weeks of treatment with osmotic pumps, the HS014-treated rats (average weight 425 g) had 20% higher body weight than the controls rats (average 360 g). When i.c.v. injections were terminated, the body weight of the twice-daily HS014-trrated rats returned to the levels of control group, whereas the rats treated with continuous infusion of HS014 remained hyperphagic and still gained weight. Blood glucose levels in the rats treated with HIS014 infusion were significantly increased. Analysis of body composition in HS014-infused rats indicated that body weight was increased due to fat deposits. These data show for the first time that chronic administration of exogenous MC4 receptor antagonist causes hyperphagia and severe obesity in rats. These data also indicate that the melanocortic control of food intake is very robust and suggest that changes induced by such treatment overcome negative feedback signals. NeuroReport 10: 711-711 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:707 / 711
页数:5
相关论文
共 24 条
  • [21] Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist
    Skuladottir, GV
    Jonsson, L
    Skarphedinsson, JO
    Mutulis, F
    Muceniece, R
    Raine, A
    Mutule, I
    Helgason, J
    Prusis, P
    Wikberg, JES
    Schiöth, HB
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) : 27 - 34
  • [22] STANLEY BG, 1986, PEPTIDES, V7, P1189
  • [23] Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion
    Thiele, TE
    Van Dijk, G
    Yagaloff, KA
    Fisher, SL
    Schwartz, M
    Burn, P
    Seeley, RJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1998, 274 (01) : R248 - R254
  • [24] VERGONI AV, 1998, IN PRESS EUR J PHARM